J&J’s soft tissue surgical robot succeeds in pivotal gastric bypass study

J&J hopes Ottava will boost its standing in the growing surgical robotics market, which is currently dominated by Intuitive Surgical. The medtech giant hopes to bolster its position in the growing surgical robotics market, which is currently dominated by Intuitive Surgical. J&J has filed for the Ottava system’s De Novo classification with the FDA. Credit: mentalmind / Shutterstock.com. Johnson & Johnson (J&J) is eyeing a De Novo classification from US regulators for its Ottava Robotic Surgical System, after the device met its key goals in a prospective gastroenterology study. During the single-arm, open-label FORTE trial (NCT06709261), 30 patients across six…

Source: Clinical Trials Arena